MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

Kodu・Aktsiate loetelu・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Suletud

4.12 2.49

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.02

Max

4.24

Põhinäitajad
By Trading Economics
Sissetulek	5.5M -28M
Müük	8.2M 13M
Kasumimarginaal	-208.694
Töötajad	172
EBITDA	8.7M -27M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+238.46% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	10. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-38M 217M
Eelmine avamishind	1.63
Eelmine sulgemishind	4.12

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

3.17 / 3.4644 Toetus ja vastupanu

Voyager Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. jaan 2026, 22:41 UTC

Omandamised, ülevõtmised, äriostud

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15. jaan 2026, 00:00 UTC

Tulu

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14. jaan 2026, 23:47 UTC

Market Talk

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14. jaan 2026, 23:44 UTC

Market Talk

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14. jaan 2026, 23:39 UTC

Market Talk

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14. jaan 2026, 23:32 UTC

Market Talk

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14. jaan 2026, 22:56 UTC

Omandamised, ülevõtmised, äriostud

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14. jaan 2026, 22:53 UTC

Omandamised, ülevõtmised, äriostud

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14. jaan 2026, 22:17 UTC

Market Talk

Global Equities Roundup: Market Talk

14. jaan 2026, 22:17 UTC

Market Talk

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14. jaan 2026, 22:09 UTC

Tulu

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14. jaan 2026, 22:08 UTC

Tulu

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14. jaan 2026, 22:08 UTC

Tulu

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14. jaan 2026, 21:53 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14. jaan 2026, 21:53 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14. jaan 2026, 21:52 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC Announces Positive Profit Alert for 2025

14. jaan 2026, 21:51 UTC

Omandamised, ülevõtmised, äriostud

Citigroup Acting as Financial Advisor to WuXi XDC

14. jaan 2026, 21:51 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC: Aims to Keep Listing Status of BioDlink

14. jaan 2026, 21:51 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14. jaan 2026, 21:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

14. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14. jaan 2026, 21:49 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14. jaan 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14. jaan 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC Makes Cash Offer for BioDlink International

14. jaan 2026, 21:13 UTC

Market Talk

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14. jaan 2026, 20:30 UTC

Market Talk

Tulu

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14. jaan 2026, 20:13 UTC

Market Talk

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14. jaan 2026, 20:08 UTC

Market Talk

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14. jaan 2026, 19:33 UTC

Market Talk

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14. jaan 2026, 19:06 UTC

Market Talk

Tulu

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Voyager Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

238.46% tõus

12 kuu keskmine prognoos

Keskmine 13.2 USD 238.46%

Kõrge 25 USD

Madal 8 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Voyager Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi Voyager Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.17 / 3.4644Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.